NCT00503763撤回2 期
Open -Label Phase IIa Trial of the Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Paraprotein level
研究概览
简要总结
The aim of the study is to evaluate the effect of statin administration on the course of progressive Smoldering Multiple Myeloma.
详细描述
In vitro data indicate that statins affect myeloma cells, mainly by inducing cell death and growth suppression.
This is a national, multicenter, phase IIa, single arm (not controlled), open label clinical trial of Simvastatin 80mg p.o. /day in a population of patients with progressive SMM. Patients will be treated with Simvastatin 40 mg and if no side effect will be seen the dose will be escalated to 80 mg for up to 18 months. All further treatment decisions after completion of the study are at the discretion of the investigator.Approximately 15 patients will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients fulfilling the criteria of SMM. (see Appendix I)
- •Patients with progressive smoldering Myeloma. (see Appendix II)
- •Age 18-80 years.
- •Signed informed consent prior to patient recruitment.
排除标准
- •Patients fulfilling diagnostic criteria of active MM .(see Appendix I)
- •Patients fulfilling diagnostic criteria of: solitary myeloma or non secreting myeloma or oligosecretory myeloma or light chain myeloma.
- •Patients on statin treatment on the day of recruitment.
- •Patients on chemotherapy or receiving steroids.
- •Patients with any contraindication to statin treatment:
- •Known intolerance or hypersensitivity to statin.
- •SGOT or SGPT above 1.5 times of upper normal level (UNL).
- •CPK above UNL
- •Concomitant treatment with macrolides and or antifungal agents (ketoconazole)
- •Creatinine level above 1.5 mg%
- •Any severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
- •Patients with second primary malignancy (except for non melanoma skin malignancy) unless they have been disease free for at least five years.
- •Patients who have a history of alcohol or drug abuse.
- •Patients who are mentally or physically unable to comply with all aspects of the study.
- •Participation to an investigational drug trial
结局指标
主要结局
Paraprotein level
时间窗: 18 months
次要结局
未报告次要终点
研究者
相似试验
Unknown
3 期
The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCIST-elevation Myocardial Infarction(STEMI)NCT01334671General Hospital of Chinese Armed Police Forces150
Unknown
4 期
Intensive Statin Treatment for STEMI Patients Undergoing Primary PCISTEMINCT01033058Beijing Chao Yang Hospital500
招募中
2 期
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorSMelanomaAtherosclerosisNCT05180942Monash University130
终止
4 期
Statins for Prevention of Disease Progression and Hospitalization in Liver CirrhosisLiver CirrhosesNCT04072601Copenhagen University Hospital, Hvidovre78
已完成
2 期
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast CancerPostmenopausalBreast CancerNCT00816244Lund University Hospital50